Kaneka Corporation (Minato, Tokyo, Japan; President: Mamoru Kadokura) has been in dispute with Xiamen Kingdomway Group Company, Pacific Rainbow International Inc., and Shenzhou Biology and Technology Co., Ltd. since March 2011, when Kaneka instituted a patent infringement action against the companies in the United States District Court for the Central District of California alleging infringement of Kaneka’s U.S. Patent No. 7,910,340 relating to coenzyme Q10(Kaneka Q10).
In April 2014, the US District Court for the Central District of California granted the Defendants’ motions for the summary judgement and denied Kaneka’s motion for summary judgement, but after and appeal by Kaneka, the Federal Circuit Court of Appeals remanded the case to District Court in June, 2015.
On November 5, 2017, Kaneka agreed to settle with Shenzhou Biology and Technology Co., Ltd. and the parties agreed to establish comprehensive arrangements for future business. The two parties have agreed that Kaneka will distribute Shenzhou’s Q10 in North America as one of its channels and that Shenzhou will distribute Kaneka’s Ubiquinol product in China. We will increase a share of the oxidized coenzyme Q10 market in North America and expand Ubiquinol market in China through this agreement.
Kaneka continues the dispute with Xiamen Kingdomway Group Company and Pacific Rainbow International Inc., for the District Court case in the Central District of California and with Zhejiang Medicine Co. Ltd and ZMC-USA, LLC for the similar case in Texas.